Biopharmaceutical companies are entitled to set a path forward and then change course, just like anyone else, so it should not come as a surprise that Sirnaomics, Inc. reassessed its financing options and chose a different road than it planned to travel down last year.
The company said back in October when it raised a $105m series D venture capital round that it was preparing...






